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Summary 32 
The G72 gene is one of the most susceptible genes to schizophrenia and is contained 33 
 2 
exclusively in the genomes of primates. The product of the G72 gene modulates the activity of 1 
D-amino acid oxidase (DAO) and is a small protein prone to aggregate, which hampers its 2 
structural studies. In addition, lack of a known structure of a homologue makes it difficult to use 3 
the homology modeling method for the prediction of the structure. Thus, we first developed a 4 
hybrid ab initio approach for small proteins prior to the prediction of the structure of G72. The 5 
approach uses three known ab initio algorithms. To evaluate the hybrid approach, we tested our 6 
prediction of the structure of the amino acid sequences whose structures were already solved 7 
and compared the predicted structures with the experimentally solved structures. Based on these 8 
comparisons, the average accuracy of our approach was calculated to be ~5 Å. We then applied 9 
the approach to the sequence of G72 and successfully predicted the structures of the N- and 10 
C-terminal domains (ND and CD, respectively) of G72. The predicted structures of ND and CD 11 
were similar to membrane-bound proteins and adaptor proteins, respectively.  12 
 13 
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Introduction 18 
About 1% of world population develops schizophrenia (1). Among all schizophrenia 19 
linkage regions, SCZD7 on chromosome 13q32-q33 (MIM 603176) is one of the most 20 
important regions (1, 2). Chumakov et al. reported overlapping genes including G30 and G72 in 21 
this region and an associated common SNP that replaces Arg30 of the G72 protein with Lys (3). 22 
In addition, quite small p value for the association of polymorphism in the G30/G72 locus (e.g. 23 
rs4517638 p < 0.00002) was reported according to recent GWAS studies (4). Transgenic mice 24 
of G72 showed behavioral alterations indicative of psychiatric disorders including abnormal 25 
motor coordination phenotype and deficits in prepulse inhibition (5). Moreover, prepulse 26 
inhibition deficits were normalized by the administration of haloperidol, an antagonist of the 27 
dopamine receptor D2. These findings indicate that the G30/G72 locus is the true-positive and 28 
robust region associated to schizophrenia. Furthermore, it has been suggested that the G30/G72 29 
locus is associated with other psychiatric disorders including bipolar disorder and Alzheimer’s 30 
disease (6, 7).  31 
The G72 protein is primate-specific and has several variants. The 153 residue variant 32 
has been found exclusively in human. The amino acid sequence of G72 lacks recognizable 33 
 3 
protein motifs that are common to other proteins. The G72 protein interacts with D-amino acid 1 
oxidase (DAO) and regulates the activity of DAO (3, 8, 9). DAO regulates the amount of 2 
intracerebral D-Ser, one of the major co-agonists of the N-methyl-D-aspartate (NMDA) 3 
receptors (10). Thus, dysfunction of G72 may cause the hypofunction of the NMDA receptors, 4 
leading to the onset of schizophrenia. This is in line with the glutamate hypothesis of 5 
schizophrenia (11).   6 
G72 also regulates the function of mitochondria by promoting mitochondrial 7 
fragmentation and dendritic arborization (12). Changes in the redox states were suggested based 8 
on various evidences including decrease in the glutathione levels in brains of patients and 9 
transgenic mice of G72 and improved mismatch negativity of patients after the treatment with 10 
reducing agents (13-15). These suggest that aberration of the redox state and mitochondria due 11 
to the dysfunction of G72 may cause schizophrenia.   12 
Because the structures of the G72 protein and its homologues have been unknown, 13 
the molecular mechanism and function of G72 are still elusive. It is difficult to apply homology 14 
modeling to predict the structure of G72 without that of a homologue. When we have no 15 
structure of a homologue, the ab initio methods may be useful to predict protein structures. 16 
Although the accuracy of the ab initio methods has been improved rapidly (16-19), most of 17 
known ab initio methods still do not predict the one best structure but do predict multiple 18 
possible structures for a query amino acid sequence. To solve this problem, we first developed a 19 
hybrid ab initio approach to predict the structures of small helical basic proteins and then 20 
applied it to predict the structure of G72.  21 
 22 
Materials and methods 23 
Secondary Structure prediction  24 
We predicted the secondary structure of G72 with the JPRED and PSIPRED 25 
algorithms prior to the prediction of the tertiary structure (20, 21).   26 
 27 
Structure prediction with the hybrid ab initio approach 28 
We produced 5 candidate models with I-TASSER, 10 candidate models with 29 
QUARK and ~20000 decoy structures with the AbinitoRelax algorithm of the Rosetta suite 30 
using the sequences of the PDB files of 2QFF, 3FEA, 2EFV, 1MN8, 1O82 and 2ZKO (16, 18, 31 
19). We chose the six sequences from the proteins that were used for the evaluation of the 32 
QUARK program based on the following criteria: helical proteins with less than 100 residues, 33 
 4 
positive isoelectric points and no prosthetic group (18). No structural information of these PDB 1 
files and their homologues was used for the prediction. Two rounds of clustering using the 2 
cluster algorithm of the Rosetta suite were performed to obtain the consensus clusters that 3 
contained the models and decoys from all of the three algorithms. For the final selection of the 4 
best model, the models and decoys in the consensus clusters were directly compared by 5 
calculating the RMSD values with the Swiss PDB Viewer by excluding 10 residues from N- 6 
and C-termini (22).  7 
Model building of ND and CD of G72 was performed with the same approach using 8 
the regions #1 – 71 and #72 – 153 of the 153 residue-long isoform. Prior to the model building, 9 
the sequence was analyzed with NCBI BLAST to define the domains based on Conserved 10 
Domain Database (23).  11 
 12 
Molecular dynamics 13 
The best ND and CD models were subject to MD simulations. The AMBER ff14SB 14 
force field was applied (24). The domains were placed in a periodic TIP3P box with the LEaP 15 
module of AMBER 14 (25). The systems were neutralized by replacing TIP3P models with Cl- 16 
ions. A 10 Å cut-off was applied to the non-bonded interactions according to the Lennard–Jones 17 
potential. Steepest descent minimization was performed followed by conjugate gradient 18 
minimization with the Particle Mesh Ewald method with constant-volume periodic boundaries 19 
and with position restraints for the protein atoms. A 200 ps heating procedure was performed 20 
from 0 to 300 K under constant volume periodic boundaries. The step size was set to 0.002 ps. 21 
Equilibration and production MD was performed with a constant pressure periodic boundary at 22 
1 atm and 300 K without position restraints. The duration of the production MD was 10 ns and 23 
30 ns for ND and CD, respectively.  Evaluation of the model structures was performed with 24 
the Ramachandran plot, Verify3D and ERRAT (26-28).  25 
 26 
Results 27 
The hybrid ab initio approach 28 
Each ab initio prediction algorithm such as I-TASSER, QUARK and AbinitoRelax 29 
of the Rosetta suite produced multiple candidate models and decoys for an amino acid sequence 30 
without template structures of homologues (Fig. 1A). We classified all these models/decoys 31 
with two rounds of clustering and found consensus clusters that contained models/decoys from 32 
all the three algorithms. The models/decoys in the consensus clusters were compared with each 33 
 5 
other to determine the final model. We call this approach the hybrid ab initio approach. We 1 
examined the accuracy of our approach using six sequences of deposited structures in Protein 2 
Data Bank (Fig. 1B). To this end, we built the structural models of these sequences without 3 
using structural information of these proteins and their homologues. In the present study, we 4 
focused on the prediction of structures of helical proteins with less than 100 residues, positive 5 
isoelectric points and no prosthetic group. All of the six proteins for the test satisfy the criteria. 6 
We focused on the helical proteins because the secondary structure prediction suggested that 7 
G72 is helix-rich (supplementary Fig. S1). After the selection of the final models, we compared 8 
the predicted structures and those deposited in Protein Data Bank. The average of the backbone 9 
root-mean-square deviation (RMSD) values between the predicted and deposited structures was 10 
~5 Å, which is close to the size of a small amino acid. Moreover, the average RMSD value 11 
further improved when 10 residues from N- and C-termini were excluded from the calculation 12 
of the RMSD of each comparison. These suggested that the core regions of the predicted 13 
structures were predicted more correctly than the terminal regions and that our approach 14 
successfully predicted correct folds (Fig. 1B, C). It is notable that our approach succeeded in 15 
choosing the one best model for each amino acid sequence out of multiple candidate 16 
models/decoys.   17 
 18 
Domain composition of the G72 protein 19 
Three variants of human G72 transcripts have been reported. Expression of the 153 20 
residue-long variant was observed in the human brain cortex (8). Only the 153 residue-long 21 
variant has been reported to interact with DAO (3, 9). In addition, the reported amino acid 22 
substitution, Arg30Lys, associated with the disorder is that of the 153 residue variant. 23 
Conserved Domain Database (23), which is a resource of the National Center for Biotechnology 24 
Information (NCBI), identified a domain from the residue number 72 to 153 within the 153 25 
residue variant (Fig. 2). We call this region the C-terminal domain (CD) and call the remaining 26 
region the N-terminal domain (ND). Most of the sequence of CD is conserved among the three 27 
human variants, whereas that of ND is not.  28 
 29 
Modeling of ND  30 
Structure prediction of ND was performed with the hybrid ab initio approach. We 31 
clustered models/decoys of ND after building models/decoys. 11 clusters were found in the first 32 
round of clustering (Fig. 3A). Two of them were consensus clusters in which the models/decoys 33 
 6 
produced by the three algorithms were included. After the second round of clustering for the 1 
consensus clusters, we found three consensus clusters. We compared the decoys/models from 2 
the three different algorithms within each of the consensus clusters by calculating the backbone 3 
RMSD between the decoys/models. Subsequently, we calculated the average of the RMSD 4 
values for each decoy/model as shown in Fig. 3C to choose the decoy/model with the smallest 5 
average RMSD as the best model. The best model was the 4th model of the 10 models that were 6 
originally produced by QUARK (Q4). We confirmed that the Q4 model shared the similar 7 
overall structure with models/decoys produced by AbinitoRelax (AR c.0.3) and I-TASSER 8 
(IT1) (Fig. 3B, C). The best model was subject to molecular dynamics (MD) simulation and 9 
reached equilibrium after ~0.5 ns, suggesting that this model structure is stable in aqueous 10 
solution (Supplementary Fig. S2). Evaluation by the Ramachandran plot, Verify3D and 11 
ERRAT indicated acceptable profiles (Table 1). The RMSD value between Q4 and IT1 was 12 
3.75 Å, whereas the value between Q4 and AR c.0.3 was 3.93 Å. These indicate diversity of the 13 
model structures produced by the different algorithms. Such an extent of the diversity is 14 
acceptable because these RMSD values were comparable to the average accuracy of the hybrid 15 
ab initio approach (~ 5 Å). The RMSD values in Supplementary Fig. S2 indicate the extent of 16 
conformational change in the course of the MD simulation with Q4 as the initial structure and 17 
were roughly 1 to 2 Å after ~0.5 ns. It is possible that the equilibrated conformations after ~0.5 18 
ns may be those that were trapped in local minima of the energy landscape. However, it is 19 
predicted that the RMSD of these conformations with respect to the true structure should be less 20 
than ~ 5 Å based on the accuracy of the hybrid ab initio approach.  21 
 22 
Modeling of CD  23 
 Modeling of CD was performed similarly to that of ND. The consensus clusters 24 
contained the models/decoys from all the three algorithms. The final comparison of the best 25 
models from the three algorithms indicated that the 8th model produced by QUARK (Q8) 26 
should be chosen as the final model (Fig. 4). This model shared the overall structure with the 27 
models/decoys from AbinitoRelax and I-TASSER (AR c.0.4 and IT2, respectively). The best 28 
model was subject to MD simulation and reached equilibrium after ~5 ns (Supplementary Fig. 29 
S3), suggesting that this model structure is stable. Evaluation by the Ramachandran plot, 30 
Verify3D and ERRAT indicated acceptable profiles (Table 2). The RMSD value between Q8 31 
and IT2 was 4.57 Å, whereas the value between Q8 and AR c.0.4 was 4.69 Å. The RMSD 32 
values in Supplementary Fig. S3 indicate the extent of conformational change in the course of 33 
 7 
the MD simulation with Q8 as the initial structure and were roughly 3 to 4 Å after ~5 ns. 1 
Although it is possible that these conformations may be trapped in local minima of the energy 2 
landscape, it is predicted that the RMSD with respect to the true structure should be less than ~5 3 
Å as was the case of ND.  4 
 5 
Distribution of surface charges 6 
Both ND and CD showed different surface charge distribution (Fig. 5). Notably, CD 7 
contains clusters of opposite charges on opposite sides of the molecule. The 30th residue is 8 
located at the center of the positively charged cluster of ND. Arg30 is on the same face as the 9 
positive charges including those of Lys4, Lys36, Arg57, Arg64 and the N-terminus (Fig. 5A).  10 
 11 
Fold search 12 
We performed a fold search with COFACTOR using the best ND model as a query 13 
structure and obtained the PDB codes of 10 structural analogues (Supplementary Table S1). 14 
Direct observation of these analogues confirmed that the analogs from Rank 1 to 4 appeared 15 
similar to ND (Fig. 6A, B), whereas the others contained inconsistent paths of polypeptide 16 
chains compared with ND (Fig. 6C). The proteins that ranked number 1 and 3 (PDB code: 17 
4X82 and 5AEZ, respectively) were membrane transporters. 4X82 is the PDB code of the 18 
extracellular domain of a Zn transporter, whereas 5AEZ is that of the transmembrane domain of 19 
an ammonium transporter. In addition, we obtained 110 similar structures to ND from a fold 20 
search using the Dali server (Supplementary Table S2). We confirmed that top ~80 structures 21 
appeared similar to ND by direct observation. Most of the ~80 structures were those of 22 
O-GlcNAc transferases (OGT). The part of OGT that resembles ND binds to the phosphate 23 
groups of UDP.  24 
A search for 10 structural analogues of the CD model with COFACTOR was 25 
performed (Supplementary Table S3). We confirmed that the analogues that ranked top, fifth 26 
and sixth had similar structures to CD by direct observation of the superposition of the 27 
structures of the CD model and the hit proteins, but the other analogues did not (Figs. 7A-E). 28 
The top-ranking PDB code 2OKC is that of the modification subunit (HsdM) of Type I DNA 29 
methyltransferases. A fold search with the Dali server was also preformed using the CD model. 30 
26 similar structures were obtained from the search (Supplementary Table S4). 18 of the 26 31 
structures were those of regulator of G protein signaling homology bundle subdomain (RH 32 
bundle subdomain) of G-protein coupled receptor kinases (GRK). We confirmed that the RH 33 
 8 
bundle subdomains are similar to CD by observing the structures of those proteins (Fig. 7D, F).  1 
 2 
 3 
Discussion  4 
We developed the hybrid ab initio approach for the positively charged small proteins 5 
that is rich in α-helices. The average backbone accuracy of the approach approximately 6 
corresponds to the size of a small amino acid. Moreover, our approach succeeded in choosing 7 
the one best structural model for an amino acid sequence out of multiple decoys/models that 8 
were produced by the known algorithms. We predicted the structures of ND and CD of G72 9 
using the approach. The predicted structures of ND and CD were rich in α-helices, which was 10 
consistent with the secondary structure contents data that were analyzed with circular dichroism 11 
(29). The surface charges of ND and CD were rich in positive charges, which may be 12 
advantageous to the interaction with human DAO whose surface is negatively charged (30, 31). 13 
Arg30Lys is the susceptibility substitution of the G72 protein. It is therefore speculated that the 14 
substitution may have an impact on the interaction with DAO because the arginine is at the 15 
center of the positive charge cluster. It is intriguing that the predicted structure of ND is similar 16 
to parts of membrane proteins and OGTs. These might suggest that ND can locate on the 17 
surface of membranes of organelles including mitochondria. Indeed, G72 was reported to locate 18 
on mitochondria and in cytosol (8, 12). We speculate that ND might bind to the phosphate 19 
groups of membrane lipids, because the part of OGT that resembles ND binds to the phosphate 20 
groups of UDP. ND is too small to be a transmembrane protein as shown in Fig 6B. In addition, 21 
the hydropathy plot did not indicate a transmembrane region in the G72 sequence.  22 
The fold searches of CD indicated that CD is similar to a part of HsdM and the RH 23 
bundle subdomain. The HsdM molecules form a homodimer (32). The predicted structure of 24 
CD is similar to the helix bundle that serves as the dimer interface of HsdM. The RH bundle 25 
subdomain functions as the binding interface with the α subunit of guanine nucleotide-binding 26 
protein, Gq (Gαq), to inhibit G-proteins (33). It was reported that two G72 molecules and four 27 
DAO molecules form a complex (8). Thus, CD might be an interface for complex formation 28 
with the other proteins including DAO, which might suggest that G72 serves as an adaptor 29 
protein.   30 
The present study developed a hybrid approach to predict protein structures and 31 
predicted the structures of the domains of the G72 protein. This approach may be useful for the 32 
prediction of structures of small nucleic acid-binding proteins, because many of these proteins 33 
 9 
are helical and positively charged. The application of this approach might be expanded to 1 
negatively charged and/or non-helical proteins in the future. The predicted structures may be 2 
useful for the functional analysis of G72 and as the target structures for the development of 3 
psychopharmaceutical drugs because mutations in G72 are presumed to contribute to the 4 
development of psychiatric disorders including schizophrenia and bipolar disorder. However, it 5 
is important to improve the accuracy of the predicted structures for efficient drug screening. The 6 
MD simulation with microsecond- to millisecond-scale may improve the accuracy of the models. 7 
The other possibility to improve the accuracy is to combine experimental data into the 8 
prediction calculation. By identifying cross-linked residues with Liquid Chromatography Mass 9 
Spectrometry after chemical cross-linking, it is possible to obtain distance restraints for the 10 
calculation. 11 
 12 
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Table 1 Validation of the final model of ND 1 
Ramachandran plot Verify3D ERRAT 
Favored 
% 
Allowed
% 
Outlier
% 
%  
95.7 4.3 0.0 94.29 100.000 
 2 
3 
 16 
Table 2 Validation of the final model of CD 1 
Ramachandran plot Verify3D ERRAT 
Favored 
% 
Allowed
% 
Outlier
% 
%  
90.0 10.0 0.0 74.39 100.000 
 2 
3 
 17 
Figure legends 1 
Fig. 1 the hybrid ab initio approach 2 
(A) Workflow of the hybrid ab initio approach. Domains were defined according to Conserved 3 
Domain Database. After producing models/decoys, two rounds of clustering were performed to 4 
find the consensus cluster. The model with the most average structure was selected as the best 5 
model before the MD analysis for the refinement and stability check. Finally the structure was 6 
evaluated with the Ramachandran plot, Verify3D and ERRAT. (B) Evaluation of the hybrid ab 7 
initio approach. The sequences of six PDB coordinates were used to test the hybrid approach. 8 
The accuracy of the approach was evaluated with the RMSD between the full-length predicted 9 
structure and experimentally solved structure (RMSD-a). RMSD-b indicates the values that 10 
were calculated by excluding 10 residues from N- and C-termini in each comparison. (C) A 11 
visual comparison of experimentally solved (left, PDB code: 3FEA) and predicted structures 12 
(right).   13 
 14 
Fig. 2 Domain definition of G72 15 
According to Conserved Domain Database (23), a domain is defined from residue 72 to 153 of 16 
the 153 residue-long isoform of G72. We termed this domain CD. The remaining region 17 
(residue 1 – 71) was termed ND.    18 
 19 
Fig. 3 Process of the selection of the best model of ND 20 
(A) Clustering process of the ND models/decoys. 22000 decoys from AbinitioRelax (AR), 5 21 
models from I-TASSER (IT) and 10 models from Quark (Q) were clustered. The clusters 22 
colored blue were the consensus clusters that contained the models/decoys from all the three 23 
algorithms.  24 
(B) Superposition of the models/decoys from AbinitioRelax (beige), I-TASSER (sky blue), 25 
Quark (magenta) in one of the consensus clusters. The location of Arg30 is shown in green.  26 
(C) The final comparisons of the models/decoys shown in (B) based on RMSD. The compared 27 
models were the 1st model from I-TASSER (IT1), 4th model from QUARK (Q4) and model 28 
c.0.3 from AbinitioRelax (AR c.0.3).  29 
 30 
Fig. 4 Final comparisons of models/decoys of CD  31 
(A) Superposition of the models/decoys from AbinitioRelax (beige), I-TASSER (sky blue), 32 
Quark (magenta) in one of the consensus clusters.  33 
 18 
(B) The final comparison of the models/decoys shown in (A) based on RMSD. The compared 1 
models were the 2nd model from I-TASSER (IT2), 8th model from QUARK (Q8) and model 2 
c.0.4 from AbinitioRelax (AR c.0.4). 3 
 4 
Fig. 5 Surface charge distribution of ND and CD 5 
Positive and negative surface charges are colored blue and red, respectively. (A) Front view of 6 
the best ND model with surface representation. Positive residues that surround Arg30 are 7 
indicated. (B) Back view of ND. (C) Front view of the best CD model. (D) Back view of CD. 8 
 9 
Fig. 6 Fold search of ND 10 
(A - C) Superposition of the ND model on 4X82 (A), 5AEZ (B) and 1QQ0 (C) that were 11 
searched by COFACTOR. 4X82 (Rank1), 5AEZ (Rank3) and 1QQ0 (Rank6) are the PDB 12 
codes of the extracellular domain of ZIP4, Mep2 ammonium transceptor and carbonic 13 
anhydrase, respectively. ND was colored sky blue, whereas the other proteins are colored gray. 14 
Shade on the protein structure in (B) indicates the thickness of a lipid bilayer. (D) The 15 
structurally aligned region of OGT (PDB code; 2XGO) with ND by the Dali server. (E) The ND 16 
model of G72. 17 
 18 
Fig. 7 Fold search of CD 19 
(A - C) Superposition of CD (sky blue) on 2OKC (A), 2OAB (B) and 1G7V (C) searched by 20 
COFACTOR. 2OKC (gray), 2OAB (gray) and 1G7V (gray) are the PDB codes of HsdM, 21 
3-deoxy-D-arabino-heptulosonate-7-phosphate synthase and 22 
2-dehydro-3-deoxyphosphooctonate aldolase, respectively. (D) The CD model (E) The structure 23 
of a part of HsdM (yellow) is aligned with that of CD in (D). The yellow and gray ribbon 24 
models form the interface of the homodimer (PDB code: 2Y7C). (F) The RH bundle subdomain 25 
of GRK2 (yellow) interacting with Gαq (pink). PDB code is 2BCJ. The RH bundle subdomain 26 
is depicted in the same orientation as CD.  27 
 28 
 29 
 30 
 31 
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Supplementary Table S1 
Top 10 identified structural analogs of ND in PDB analyzed by COFACTOR  
 
Rank PDB Hit TM-scorea RMSDb Identityc Coveraged 
1 4x82B 0.564 3.32 0.057 0.944 
2 3nyyA 0.551 3.18 0.015 0.915 
3 5aezA 0.537 3.36 0.043 0.873 
4 5af3A 0.535 3.09 0.056 0.845 
5 3c8vC 0.530 3.38 0.092 0.873 
6 1qq0A 0.521 3.77 0.030 0.901 
7 3c8iB 0.520 3.41 0.081 0.859 
8 3r1wA 0.517 3.57 0.030 0.901 
9 3i5oB 0.517 2.98 0.000 0.789 
10 2y35A 0.516 3.29 0.059 0.873 
 
a TM-score of the structural alignment between the query structure and known 
structures in the PDB library. 
b RMSD between residues that are structurally aligned by TM-align. 
c The sequence identity in the structurally aligned region. 
d Coverage represents the coverage of the alignment by TM-align and is equal to the 
number of structurally aligned residues divided by length of the query protein. 
 
 
Supplementary Table S2 
Structural analogs of ND in PDB analyzed by the Dali server  
 
No Chain Za rmsd lalib nresc %idd Description 
1 2xgo-B 3.2 7 54 541 6 XCOGT; 
2 2xgs-A 3.2 7 54 542 6 XCOGT; 
3 2xgm-B 3.1 7.1 54 542 6 XCOGT; 
4 2vsy-B 3.1 7.1 54 547 6 XCC0866; 
5 2jlb-B 3.1 7.1 54 548 6 XCC0866; 
 2 
6 1pjt-A 3 3 49 449 10 SIROHEME SYNTHASE; 
7 1pjq-A 2.9 3 49 448 10 SIROHEME SYNTHASE; 
8 1pjs-A 2.9 3 49 444 10 SIROHEME SYNTHASE; 
9 5a01-A 2.7 7.4 53 681 8 O-GLYCOSYLTRANSFERASE; 
10 4gyw-C 2.6 6.9 54 674 13 UDP-N-ACETYLGLUCOSAMINE--PEPTIDE N- 
11 4xif-A 2.6 7.2 53 702 13 UDP-N-ACETYLGLUCOSAMINE--PEPTIDE N- 
12 4gz3-C 2.6 6.9 54 674 13 UDP-N-ACETYLGLUCOSAMINE--PEPTIDE N- 
13 3pe4-C 2.6 6.9 54 674 13 UDP-N-ACETYLGLUCOSAMINE--PEPTIDE N- 
14 3pe3-A 2.6 7.2 53 701 13 UDP-N-ACETYLGLUCOSAMINE--PEPTIDE N- 
15 4xi9-A 2.6 6.9 54 698 13 UDP-N-ACETYLGLUCOSAMINE--PEPTIDE N- 
16 5a01-B 2.6 7.4 53 681 8 O-GLYCOSYLTRANSFERASE; 
17 4cdr-D 2.6 6.9 54 698 13 UDP-N-ACETYLGLUCOSAMINE--PEPTIDE 
18 4xi9-C 2.6 6.9 54 698 13 UDP-N-ACETYLGLUCOSAMINE--PEPTIDE N- 
19 4cdr-B 2.6 6.9 54 698 13 UDP-N-ACETYLGLUCOSAMINE--PEPTIDE 
20 3tax-A 2.6 6.9 54 695 13 UDP-N-ACETYLGLUCOSAMINE--PEPTIDE N- 
21 4n3b-A 2.6 6.9 54 697 13 UDP-N-ACETYLGLUCOSAMINE--PEPTIDE N- 
22 5bnw-A 2.6 6.9 54 694 13 UDP-N-ACETYLGLUCOSAMINE--PEPTIDE N- 
23 3pe3-C 2.6 6.9 54 701 13 UDP-N-ACETYLGLUCOSAMINE--PEPTIDE N- 
24 4xif-C 2.6 7.2 53 702 13 UDP-N-ACETYLGLUCOSAMINE--PEPTIDE N- 
25 3tax-C 2.6 6.9 54 695 13 UDP-N-ACETYLGLUCOSAMINE--PEPTIDE N- 
26 5c1d-A 2.6 6.9 54 695 13 UDP-N-ACETYLGLUCOSAMINE--PEPTIDE N- 
27 4gz5-C 2.6 6.9 54 700 13 UDP-N-ACETYLGLUCOSAMINE--PEPTIDE N- 
28 4ay6-A 2.6 7.2 53 698 13 UDP-N-ACETYLGLUCOSAMINE--PEPTIDE 
29 4ay6-D 2.6 6.9 54 698 13 UDP-N-ACETYLGLUCOSAMINE--PEPTIDE 
30 4ay5-A 2.6 6.9 54 698 13 UDP-N-ACETYLGLUCOSAMINE--PEPTIDE N-ACETYLGLUCOSAM 
31 4ay5-B 2.6 6.9 54 698 13 UDP-N-ACETYLGLUCOSAMINE--PEPTIDE N-ACETYLGLUCOSAM 
32 4gz3-A 2.6 6.9 54 695 13 UDP-N-ACETYLGLUCOSAMINE--PEPTIDE N- 
33 4cdr-C 2.6 6.9 54 698 13 UDP-N-ACETYLGLUCOSAMINE--PEPTIDE 
34 4xif-B 2.6 7.2 53 702 13 UDP-N-ACETYLGLUCOSAMINE--PEPTIDE N- 
35 4gyw-A 2.6 6.9 54 695 13 UDP-N-ACETYLGLUCOSAMINE--PEPTIDE N- 
36 4xi9-D 2.6 6.9 54 698 13 UDP-N-ACETYLGLUCOSAMINE--PEPTIDE N- 
 3 
37 4cdr-A 2.6 6.9 54 698 13 UDP-N-ACETYLGLUCOSAMINE--PEPTIDE 
38 4xif-D 2.6 7.4 53 702 13 UDP-N-ACETYLGLUCOSAMINE--PEPTIDE N- 
39 3pe4-A 2.6 6.9 54 695 13 UDP-N-ACETYLGLUCOSAMINE--PEPTIDE N- 
40 3pe3-D 2.6 6.9 54 701 13 UDP-N-ACETYLGLUCOSAMINE--PEPTIDE N- 
41 3pe3-B 2.6 6.9 54 701 13 UDP-N-ACETYLGLUCOSAMINE--PEPTIDE N- 
42 4n3a-A 2.6 7.2 53 697 13 UDP-N-ACETYLGLUCOSAMINE--PEPTIDE N- 
43 4ay5-C 2.6 6.9 54 698 13 UDP-N-ACETYLGLUCOSAMINE--PEPTIDE N-ACETYLGLUCOSAM 
44 4ay6-C 2.6 6.9 54 698 13 UDP-N-ACETYLGLUCOSAMINE--PEPTIDE 
45 4gz6-A 2.6 6.9 54 700 13 UDP-N-ACETYLGLUCOSAMINE--PEPTIDE N- 
46 4gz6-C 2.6 7 52 700 13 UDP-N-ACETYLGLUCOSAMINE--PEPTIDE N- 
47 5a01-C 2.6 7.4 53 681 8 O-GLYCOSYLTRANSFERASE; 
48 4xi9-B 2.6 6.9 54 698 13 UDP-N-ACETYLGLUCOSAMINE--PEPTIDE N- 
49 4n3c-A 2.6 6.9 54 697 13 UDP-N-ACETYLGLUCOSAMINE--PEPTIDE N- 
50 4gyy-A 2.6 6.9 54 693 13 UDP-N-ACETYLGLUCOSAMINE--PEPTIDE N- 
51 4n39-A 2.6 6.9 54 697 13 UDP-N-ACETYLGLUCOSAMINE--PEPTIDE N- 
52 4gz6-B 2.6 6.9 54 700 13 UDP-N-ACETYLGLUCOSAMINE--PEPTIDE N- 
53 4gyy-C 2.6 6.9 54 671 13 UDP-N-ACETYLGLUCOSAMINE--PEPTIDE N- 
54 4ay5-D 2.6 6.9 54 698 13 UDP-N-ACETYLGLUCOSAMINE--PEPTIDE N-ACETYLGLUCOSAM 
55 4ay6-B 2.6 6.9 54 698 13 UDP-N-ACETYLGLUCOSAMINE--PEPTIDE 
56 2jlb-A 2.5 7 54 548 6 XCC0866; 
57 5djs-B 2.5 7 53 520 15 TETRATRICOPEPTIDE TPR_2 REPEAT PROTEIN; 
58 5djs-A 2.5 7 53 520 15 TETRATRICOPEPTIDE TPR_2 REPEAT PROTEIN; 
59 5djs-C 2.5 7 53 520 15 TETRATRICOPEPTIDE TPR_2 REPEAT PROTEIN; 
60 2xgo-A 2.5 7.1 52 548 6 XCOGT; 
61 2vsy-A 2.5 7.1 54 547 6 XCC0866; 
62 2vsn-B 2.5 7.1 52 534 6 XCOGT; 
63 4gz6-D 2.5 7 52 700 13 UDP-N-ACETYLGLUCOSAMINE--PEPTIDE N- 
64 4gz5-A 2.5 6.9 54 700 13 UDP-N-ACETYLGLUCOSAMINE--PEPTIDE N- 
65 4gz5-B 2.5 6.9 54 700 13 UDP-N-ACETYLGLUCOSAMINE--PEPTIDE N- 
66 4gz5-D 2.5 6.9 54 700 13 UDP-N-ACETYLGLUCOSAMINE--PEPTIDE N- 
67 2xgm-A 2.5 7.2 52 512 6 XCOGT; 
68 2xa2-A 2.4 6.1 50 412 6 TREHALOSE-SYNTHASE TRET; 
 4 
69 2vsn-A 2.4 7.1 52 534 6 XCOGT; 
70 2bnk-B 2.4 3.1 46 64 7 EARLY PROTEIN GP16.7; 
71 2c5r-F 2.4 3.3 47 63 6 EARLY PROTEIN P16.7; 
72 2c5r-B 2.4 3.3 47 63 6 EARLY PROTEIN P16.7; 
73 1zae-A 2.3 2.7 47 70 4 EARLY PROTEIN GP16.7; 
74 4n9w-A 2.3 6.2 52 360 12 
GDP-MANNOSE-DEPENDENT 
ALPHA-(1-2)-PHOSPHATIDYLINO 
75 2c5r-E 2.3 3.3 47 63 6 EARLY PROTEIN P16.7; 
76 2c5r-D 2.3 3.3 47 63 6 EARLY PROTEIN P16.7; 
77 2bnk-A 2.3 3 45 64 7 EARLY PROTEIN GP16.7; 
78 2c5r-C 2.3 3.3 47 63 6 EARLY PROTEIN P16.7; 
79 2c5r-A 2.3 3.3 47 63 6 EARLY PROTEIN P16.7; 
80 1pjt-B 2.3 3.5 51 456 10 SIROHEME SYNTHASE; 
81 2x6q-B 2.3 6.2 49 409 6 TREHALOSE-SYNTHASE TRET; 
82 5hes-A 2.2 2.9 55 288 5 MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE ML 
83 4ae4-B 2.2 3.1 51 115 10 UBIQUITIN-ASSOCIATED PROTEIN 1; 
84 2dah-A 2.2 2.9 43 54 7 UBIQUILIN-3; 
85 1pjq-B 2.2 3.2 48 456 13 SIROHEME SYNTHASE; 
86 3q3e-B 2.2 7.4 50 596 4 HMW1C-LIKE GLYCOSYLTRANSFERASE; 
87 2xmp-A 2.2 6.1 50 412 6 TREHALOSE-SYNTHASE TRET; 
88 1zae-B 2.2 3.5 48 70 6 EARLY PROTEIN GP16.7; 
89 3g6i-A 2.2 5.3 57 200 4 PUTATIVE OUTER MEMBRANE PROTEIN, PART OF CARBOHYD 
90 1pjs-B 2.2 3.5 51 455 10 SIROHEME SYNTHASE; 
91 3fx3-B 2.1 4.1 57 231 9 CYCLIC NUCLEOTIDE-BINDING PROTEIN; 
92 2x49-A 2.1 3.1 50 333 4 INVASION PROTEIN INVA; 
93 2fgy-A 2.1 3.1 45 471 4 CARBOXYSOME SHELL POLYPEPTIDE; 
94 3q3i-A 2.1 7.4 52 620 4 HMW1C-LIKE GLYCOSYLTRANSFERASE; 
95 3q3h-A 2.1 7.5 50 620 4 HMW1C-LIKE GLYCOSYLTRANSFERASE; 
96 3q3e-A 2.1 7 52 620 4 HMW1C-LIKE GLYCOSYLTRANSFERASE; 
97 4x7m-A 2.1 6 52 493 6 UNCHARACTERIZED PROTEIN; 
98 4x6l-C 2.1 6 52 493 6 TARM; 
99 4x6l-B 2.1 6 52 493 6 TARM; 
 5 
100 5jem-F 2.1 5.3 37 42 5 INTERFERON REGULATORY FACTOR 3; 
101 2bwe-G 2.1 3.1 44 46 9 DSK2; 
102 2bwe-Q 2.1 3.1 44 47 9 DSK2; 
103 2bwe-R 2.1 3.2 44 46 9 DSK2; 
104 1l8y-A 2 3 45 83 7 UPSTREAM BINDING FACTOR 1; 
105 3q3h-B 2 7 52 595 4 HMW1C-LIKE GLYCOSYLTRANSFERASE; 
106 3q3i-B 2 7.4 50 593 4 HMW1C-LIKE GLYCOSYLTRANSFERASE; 
107 3s28-E 2 5.8 52 781 4 SUCROSE SYNTHASE 1; 
108 1wgn-A 2 3.6 46 63 7 UBIQUITIN ASSOCIATED PROTEIN; 
109 5cra-A 2 5.2 54 172 11 SDEA; 
110 4un2-B 2 2.7 39 43 13 UBIQUITIN;   
 
a Z-score of the structural alignment between the query structure and known structures 
in the PDB library. 
b Length of the alignment between the query structure and known structures. 
c Number of aligned residues.  
d The sequence identity (%) in the structurally aligned region. 
 
 
Supplementary Table S3 
Top 10 identified structural analogs of CD in PDB analyzed by COFACTOR  
 
Rank PDB Hit TM-score a RMSD b Identity c Coverage d 
1 2okcB1 0.560 2.53 0.048 0.768 
2 1oabB 0.544 3.83 0.049 0.927 
3 1g7vA 0.539 3.84 0.038 0.890 
4 3fs2B 0.538 3.87 0.049 0.915 
5 2nrjA 0.534 3.38 0.038 0.829 
6 4k82A 0.533 3.91 0.050 0.939 
7 3tmqA 0.530 4.00 0.062 0.915 
8 4ur5A 0.526 3.88 0.104 0.915 
9 3t4cA 0.526 3.87 0.061 0.866 
 6 
10 3e9aA 0.516 3.66 0.049 0.878 
 
a TM-score of the structural alignment between the query structure and known 
structures in the PDB library. 
b RMSD between residues that are structurally aligned by TM-align. 
c The sequence identity in the structurally aligned region. 
d Coverage represents the coverage of the alignment by TM-align and is equal to the 
number of structurally aligned residues divided by length of the query protein. 
 
 
Supplementary Table S4 
Structural analogs of CD in PDB analyzed by the Dali server  
 
No Chain Za rmsd lalib nresc %idd Description 
1 3uzt-A 2.9 3.3 56 586 7 BETA-ADRENERGIC RECEPTOR KINASE 1; 
2 3pvu-A 2.7 3.3 57 609 9 BETA-ADRENERGIC RECEPTOR KINASE 1; 
3 2bcj-A 2.6 3.4 57 624 9 G-PROTEIN COUPLED RECEPTOR KINASE 2; 
4 1ym7-D 2.6 3.4 57 599 9 BETA-ADRENERGIC RECEPTOR KINASE 1; 
5 2acx-B 2.6 3.5 58 492 5 G PROTEIN-COUPLED RECEPTOR KINASE 6; 
6 3nyo-A 2.6 3.3 58 553 5 G PROTEIN-COUPLED RECEPTOR KINASE 6; 
7 2bv1-A 2.5 3.2 56 134 14 REGULATOR OF G-PROTEIN SIGNALLING 1; 
8 5do9-F 2.5 3.8 56 134 13 GUANINE NUCLEOTIDE-BINDING PROTEIN G(Q) SUBUNIT A 
9 1ym7-A 2.5 3.4 57 608 9 BETA-ADRENERGIC RECEPTOR KINASE 1; 
10 1ym7-B 2.5 3.4 57 608 9 BETA-ADRENERGIC RECEPTOR KINASE 1; 
11 3nyn-B 2.5 3.4 57 553 5 G PROTEIN-COUPLED RECEPTOR KINASE 6; 
12 5do9-D 2.4 3.4 54 134 15 GUANINE NUCLEOTIDE-BINDING PROTEIN G(Q) SUBUNIT A 
13 5do9-B 2.4 3.8 56 134 13 GUANINE NUCLEOTIDE-BINDING PROTEIN G(Q) SUBUNIT A 
14 3v5w-A 2.4 3.3 56 623 5 G-PROTEIN COUPLED RECEPTOR KINASE 2; 
15 3nyn-A 2.4 3.4 58 553 5 G PROTEIN-COUPLED RECEPTOR KINASE 6; 
16 2gtp-C 2.3 3.3 56 132 14 GUANINE NUCLEOTIDE-BINDING PROTEIN G(I), ALPHA-1 
17 2gtp-D 2.3 3.3 56 132 14 GUANINE NUCLEOTIDE-BINDING PROTEIN G(I), ALPHA-1 
18 3cik-A 2.3 3.4 58 619 7 BETA-ADRENERGIC RECEPTOR KINASE 1; 
 7 
19 4amq-A 2.2 3.8 55 341 7 L544; 
20 1emu-A 2.1 3.7 58 132 5 AXIN; 
21 3c51-B 2.1 3.2 50 461 6 RHODOPSIN KINASE; 
22 4ekd-B 2.1 3.1 56 132 9 GUANINE NUCLEOTIDE-BINDING PROTEIN G(Q) SUBUNIT A 
23 1dk8-A 2 3.5 58 147 5 AXIN; 
24 4ekc-D 2 3.2 56 128 9 GUANINE NUCLEOTIDE-BINDING PROTEIN G(Q) SUBUNIT A 
25 4gou-A 2 3.4 56 507 13 EHRGS-RHOGEF; 
26 3c4w-B 2 3.3 53 519 6 RHODOPSIN KINASE; 
 
a Z-score of the structural alignment between the query structure and known structures 
in the PDB library. 
b Length of the alignment between the query structure and known structures. 
c Number of aligned residues.  
d The sequence identity (%) in the structurally aligned region. 
 
 
Supplementary Fig. S1  
Secondary structure prediction 
Kato and Fukui
This figure illustrates the secondary structure prediction within G72 by the JPRED and 
PSIPRED algorithms. H and E indicate α-helix and extended structure (β-strand), 
respectively. 
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Supplementary Fig. S2  
Results of the MD simulation of the ND model 
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(A) Time course of the RMSD values between the initial structure and trajectories in the 
MD simulation.  
(B)  Superposition of the initial (gray) and final (green) trajectories in the MD 
simulation. 
  
Supplementary Fig. S3  
Results of the MD simulation of the CD model 
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(A) Time course of the RMSD values between the initial structure and trajectories in the 
MD simulation.   
(B) Superposition of the initial (gray) and final (sky blue) trajectories in the MD 
simulation. 
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